Image Credits: Canva
Heart attacks and strokes are among the leading causes of death globally, with millions suffering from cardiovascular diseases (CVD) every year. There are more than seven million people in the UK alone, with about 100,000 patients experiencing heart attacks annually. However, a group of researchers at University College London (UCL) estimate that one 'polypill' taken daily day could eliminate a majority of these cases dramatically lowering death tolls.
The proposed polypill, a combination of a statin and three blood pressure-lowering drugs, has been under study for over two decades. Experts argue that introducing this pill universally for individuals aged 50 and above could be more effective than the current NHS Health Check, which assesses risk factors every five years for those aged between 40 and 74.
Studies have repeatedly proven the effectiveness of the polypill in preventing CVD. A groundbreaking 2019 study in The Lancet found that five years' use of the polypill cut the risk of heart attack and stroke by a third. In addition, previous modelling analyses have estimated that if given universally to people over 55, the polypill might be able to prevent 80% of heart attacks and strokes.
Today, the NHS Health Check follows a risk-based model in which patients are tested for CVD risk factors and treated with drugs accordingly. Yet, as per UCL's study, this system has serious flaws:
Low Uptake: Just 40% of those eligible for the NHS Health Check choose to have it, leaving a considerable number of at-risk patients undiagnosed and untreated.
Ineffective Prediction of Risk: The majority of heart attacks and strokes happen to people at average risk levels, thus making it challenging to identify the need for intervention effectively.
Limited Effectiveness: Even at maximum take-up, the NHS Health Check programme is predicted to have fewer health impacts compared to a polypill initiative applied to the whole population.
One of the big benefits of the polypill is that it is so easy. In contrast to the existing screening-based model, the polypill scheme would not involve complicated medical tests or lengthy risk assessments. Instead, people reaching 50 would just have to fill out a few questions to determine possible side effects before they were prescribed.
Professor Aroon Hingorani of the UCL Institute of Cardiovascular Science, one of the strongest proponents of this scheme, says:
"Finally, the time is now to do much better on prevention. A population approach would prevent a lot more heart attacks and strokes than is done today with a strategy of trying to target a smaller group only."
Aside from the possible health implications, the polypill is also an economic solution. The drugs used are off-patent, thus cheap to produce and distribute. With the vast economic cost of managing CVD-related illnesses, a preventive model could result in substantial cost-saving for the NHS in the future.
The polypill has been proven to be effective by numerous international trials. In 2019, a randomised trial in rural Iran discovered that participants who took the polypill for five years had a 34% reduced risk of having a heart attack or stroke compared to non-participants.
Likewise, modelling research has indicated that even if only 8% of people aged over 50 took up the polypill regimen, it would still be more beneficial to their health than the NHS Health Check programme.
One of the main objections to the polypill strategy is the suggestion that it might result in the unnecessary medicalisation of a significant proportion of the population. But, it is argued, it should be considered as a preventative measure, not as mass medication.
Professor Sir Nicholas Wald of UCL's Institute of Health Informatics explains:
"Instead of being a 'medicalisation' of a significant proportion of the population, a polypill programme is a prevention measure to prevent an individual from becoming a patient."
He compares it with public health measures like water fluoridation or compulsory seatbelts—interventions that have been shown to have a significant impact in reducing public health danger at low individual cost.
With the evidence in favour of the polypill's effectiveness and viability overwhelming, experts are calling on the NHS to act now. It is their belief that substituting the NHS Health Check with a polypill-based prevention program could be the UK government's flagship policy under its pledge to put disease prevention ahead of cure.
As Professor Hingorani points out, "The status quo is not a justifiable option." With CVD still a major cause of death globally, taking a population-wide polypill approach could be a turning point for preventative medicine, potentially saving thousands of lives annually. The question now is whether the NHS will take up this call and establish a policy with the potential to transform the prevention of cardiovascular disease on a national level.
Mindless use of weight loss drugs can cause the weight to return later. (Photo credit: iStock)
Weight loss drugs appeal to many for their convenience, but according to some experts, there are a number of noteworthy side effects. From rapid weight gain to sagging skin, several side effects of weight loss drugs have been identified through studies. Now, new research has found that weight loss drugs can cause more muscle loss than clinical expectations. The results, presented at the American College of Physicians Internal Medicine (ACP-IM) meeting in San Francisco, add to existing evidence on the possible adverse effects of GLP-1.
When a person loses a considerable amount of weight, they also lose bone mass, muscle mass, and some connective tissue. Experts at the University of North Carolina at Chapel Hill found that no studies directly associate muscle loss with a decline in physical function or strength. However, this clinical gap underscores the need to assess strength and mobility alongside weight loss in patients receiving this therapy. The systematic review identified 36 randomised clinical trials that measured changes in muscle mass and fat among adults using incretin-based obesity medications such as tirzepatide, dulaglutide, or semaglutide.
Each study measured body composition using MRI, CT scans, and bioelectrical impedance analysis. Most of them used DEXA along with other methods to obtain information about lean muscle mass, bone mineral density, and the distribution of body fat. The average age of participants ranged from 20 to 63.7 years. Only four studies included participants aged 60 years and above. None of the studies focused on adults aged 65 years or older.
Researchers noted a concerning trend: patients’ estimated muscle loss exceeded the 25 per cent threshold. Clinicians had expected a 25 per cent reduction, but not more than that. Experts also found that 68 per cent of people who used the drugs exceeded the 25 per cent benchmark, compared to 50 per cent of those who relied on placebos and lifestyle interventions. None of the studies measured whether the loss of muscle mass was correlated with function or strength loss.
Despite being a concerning side effect of weight loss drugs, muscle mass is likely to diminish anyway with age. Additionally, the loss is more significant in older adults. Therefore, doctors advise caution when prescribing these drugs to individuals who are more prone to losing muscle function at an advanced age. Ideally, doctors should recommend exercise or physical therapy to patients taking weight loss medications.
The final word
According to experts, weight loss drugs do have a positive side — and that extends beyond obesity treatment. These drugs are also beneficial for diabetes and help reduce the risk of cardiovascular disease. However, it is important to support treatment with the right kind of diet and a proper exercise regimen. Solely depending on the medication can lead to weight gain once it is discontinued. Therefore, for healthy weight loss, it is best to rely on sustainable methods for long-lasting results.
Sadhguru recommended some tips for sustainable weight loss. (Photo credit: AI generated)
Indian guru and founder of the Isha Foundation, Sadhguru, offers a different perspective on life and mental health. In a 2025 talk, he spoke about weight loss. At a time when obesity, metabolic, and lifestyle disorders are at an all-time high, there is an urgent need to revisit and fix the way one eats. While many turn to diet fads and practise calorie or food group restrictions, Sadhguru recommends the contrary. The 68-year-old emphasises the importance of sustainable weight management through balanced choices, mindful eating and meals aligned with the body’s natural rhythm.
Many people aim to lose weight to deal with body image issues or to prepare for a special upcoming occasion. However, according to Sadhguru, one must not try to force discipline through restriction, but instead allow the body to regulate itself efficiently while maintaining energy levels. If you are looking for foods to include in your diet for sustainable weight loss, here are some recommendations:
Constipation is a consequence of poor gut health. (Photo credit: iStock)
Eat healthy meals and follow a proper diet plan; your diet must be balanced—many have grown up listening to these healthy recommendations. However, little do we realise just how much difference healthy habits make to our lives. Even when it comes to constipation, one barely understands the long-term repercussions of irregular trips to the loo and how this may impact overall health. According to a 2023 review, prominent differences can be noticed in the gut microbiomes of 'slowpokes' and 'speeders.' Because the gut is strongly linked to overall health, there are several health implications that often go unnoticed.
Constipation refers to a state wherein one fails to pass stools at least three times a week. Slow transit, too, is associated with inflammatory and metabolic disorders—and even Parkinson’s disease. Experts say that identifying microbiome profiles linked to gut transit time could help develop a fresh approach to treating and managing these conditions. Experts involved in the study explained how bidirectional interactions between transit time and gut microbiota provide a useful way to understand gut microbiome variations in both disease and health.
Experts say that the gut microbiome, in both activity and composition, plays a crucial role in health. From diet to exercise, it can be shaped by various factors. For this, experts evaluated the impact of holding in stool and its consequent effects on health. They analysed previously published research on gut transit time, diet, gut microbiome composition, stool consistency, and metabolites released. Experts found that the studies involved thousands of participants—both healthy individuals and those dealing with comorbidities such as liver cirrhosis, irritable bowel syndrome and constipation. However, this required swallowable capsules with sensors to track their journey through the digestive tract.
Another method used was the Bristol Stool Scale—a diagnostic tool that classifies stool based on whether it resembles hard pellets or watery mush. Some studies also tracked how long participants took to pass sweetcorn or blue dye. The goal was the same — estimating how long food remains in the colon. The longer it stays, the more time bacteria have to regulate gut acidity, ferment components, and produce metabolites that influence overall health.
The research team yielded interesting results — people with faster gut transit had different microbiomes compared to those with slower transit times. This helped provide better predictions for gut microbiota than a simple test alone. It was also found that faster gut transit times were associated with microbiomes dominated by faster-growing species that thrived on a low-fat, high-carbohydrate diet. Slower transit times, however, were linked to microbiomes influenced by diets high in protein. These extremes can reduce gut microbiome diversity compared to average transit times. Therefore, both fast and slow movement create environments where specific species dominate.
Collectively, the research showed that gut transit time is an overlooked tool for understanding how the gut functions, its role in overall health, and how people respond to treatments such as probiotics. This could also explain why the same gut health advice does not work for everyone. Two people can consume the same meal and still show different results, suggesting that an individual's gut rhythm can help tailor dietary advice and treatment to suit their body.
The research is published in the journal Gut.
© 2024 Bennett, Coleman & Company Limited